Microbial Diversity in Mechanisms of Disulfide Bond Formation and Reduction

二硫键形成和还原机制的微生物多样性

基本信息

  • 批准号:
    8434208
  • 负责人:
  • 金额:
    $ 68.12万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1989
  • 资助国家:
    美国
  • 起止时间:
    1989-06-01 至 2015-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): We will establish the nature of two novel protein disulfide bond-forming pathways found in certain bacteria and archaea. E. coli and many other bacteria use two enzymes to introduce disulfide bonds into proteins. DsbA directly joins the cysteines of proteins into disulfide bonds while DsbB reoxidizes and thus regenerates active DsbA. Many other bacteria, including Mycobacterium tuberculosis (Mtb), appear to use a homologue of human vitamin K epoxide reductase, VKOR, for disulfide bond formation instead of DsbB. Mtb VKOR can substitute for DsbB in E. coli. We will characterize the mycobacterial VKOR-based disulfide-bond forming system by defining which gene products comprise this oxidative pathway, expressing candidate genes in both E. coli and Mycobacterium smegmatis (which is more tractable than Mtb). In certain archaea, we have obtained evidence for another unusual pathway for disulfide bond formation in the cytoplasm. These archaea contain two VKORs, one cytoplasmically-oriented and apparently involved in cytoplasmic disulfide bond formation. We will verify this pathway and identify the cytoplasmic substrate (a cytoplasmic "DsbA"?) that this VKOR oxidizes. We will test the proposed role of this VKOR by expressing and manipulating candidate genes both in E. coli and the archaeon Sulfolobus solfataricus. The array of assays and genetic techniques developed in our lab for analyzing disulfide bond formation in the cytoplasm and periplasm will greatly facilitate these studies and those carried out in other laboratories. In our laboratory, we have evolved strains of E. coli that use novel pathways for disulfide bond formation or reduction. We hypothesize that there are other prokaryotes that use these same electron transfer pathways naturally. We will test this hypothesis as follows: we will use bioinformatic analyses that we have developed to assess the capacity of other organisms to make disulfide bonds. We will then use bioinformatic anlaysis of bacterial genomes that have been sequenced to identify prokaryotes that may lack the genes for the pathways E. coli uses for these purposes, but contain genes whose products might constitute one of the novel pathways. We will then study the properties of these candidate genes from other organisms when they are expressed in E. coli and within the native organism itself. We will study DsbB and VKOR function using a chemical biology approach to obtain small molecules that are inhibitors of DsbB and VKOR. Using a highly sensitive assay for disulfide bond formation, we will screen a large library of chemicals for inhibition of E. coli DsbB and Mtb VKOR. These chemicals will be used to dissect out the steps in the action of these two proteins, to define sites of action through resistant-mutations, and to do comparative studies of VKORs and DsbB. The inhibitors will also be screened for their activity as candidates for development as potential antibiotics against tuberculosis and as anti-coagulants. (Human VKOR is a component of the blood coagulation pathway.)
描述(由申请人提供):我们将确定在某些细菌和古菌中发现的两种新的蛋白质二硫键形成途径的性质。大肠杆菌和许多其他细菌使用两种酶将二硫键引入蛋白质中。DsbA直接将蛋白质的半胱氨酸连接成二硫键,而DsbB重新氧化,从而再生活性的DsbA。许多其他细菌,包括结核分枝杆菌(Mtb),似乎使用人类维生素K环氧化物还原酶VKOR的同系物来形成二硫键,而不是DsbB。在大肠杆菌中,MTB VKOR可以替代DsbB。我们将通过定义哪些基因产物包括这一氧化途径,在大肠杆菌和污垢分枝杆菌(比Mtb更容易)中表达候选基因,来表征基于分枝杆菌VKOR的二硫键形成系统。在某些古生菌中,我们已经获得了细胞质中另一种不寻常的二硫键形成途径的证据。这些古菌含有两个VKOR,一个面向细胞质,显然参与了细胞质二硫键的形成。我们将验证这一途径并确定细胞质底物(细胞质“DsbA”?)这种VKOR被氧化了。我们将通过在大肠杆菌和古细菌Sulfolobus solfararicus中表达和操作候选基因来测试这种VKOR的拟议作用。我们实验室开发的用于分析细胞质和周质中二硫键形成的一系列分析和基因技术将极大地促进这些研究和在其他实验室进行的研究。在我们的实验室中,我们已经进化出使用新的途径形成或还原二硫键的大肠杆菌菌株。我们假设有其他原核生物自然地使用这些相同的电子转移途径。我们将对这一假设进行如下检验:我们将使用我们开发的生物信息学分析来评估其他生物形成二硫键的能力。然后,我们将使用已经测序的细菌基因组的生物信息学分析来识别原核生物,这些原核生物可能缺乏大肠杆菌用于这些目的的途径的基因,但包含其产物可能构成其中一种新途径的基因。然后,我们将研究这些来自其他生物体的候选基因在大肠杆菌和天然生物体中表达时的特性。我们将使用化学生物学方法研究DsbB和VKOR的功能,以获得DsbB和VKOR的抑制剂小分子。使用高灵敏的二硫键形成试验,我们将筛选大量抑制E.ColiDsbB和Mtb VKOR的化学物质。这些化学物质将被用来剖析这两种蛋白质的作用步骤,通过耐药突变确定作用部位,并对VKOR和DsbB进行比较研究。这些抑制剂还将被筛选出它们的活性,作为潜在的抗结核病抗生素和抗凝血剂开发的候选药物。(人类VKOR是凝血途径的一个组成部分。)

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Dana Boyd其他文献

Dana Boyd的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Dana Boyd', 18)}}的其他基金

Microbial Diversity in Mechanisms of Disulfide Bond Formation and Reduction
二硫键形成和还原机制的微生物多样性
  • 批准号:
    8610924
  • 财政年份:
    1989
  • 资助金额:
    $ 68.12万
  • 项目类别:

相似海外基金

EPIphANy (Evaluation of Pharmacological Interactions with Anticoagulants in caNcer patients) program - prostate cancer cohort
EPIPHANy(癌症患者抗凝药理相互作用的评估)计划 - 前列腺癌队列
  • 批准号:
    479295
  • 财政年份:
    2023
  • 资助金额:
    $ 68.12万
  • 项目类别:
    Operating Grants
Inhibitors of Human Factor XIIIa as New Anticoagulants
人类因子 XIIIa 抑制剂作为新型抗凝剂
  • 批准号:
    10629057
  • 财政年份:
    2023
  • 资助金额:
    $ 68.12万
  • 项目类别:
Establishment of comprehensive monitoring of direct oral anticoagulants (DOACs) for clinical application
建立临床应用直接口服抗凝剂(DOAC)综合监测体系
  • 批准号:
    23K06906
  • 财政年份:
    2023
  • 资助金额:
    $ 68.12万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Interactions of Enzyme-Inducing Antiepileptic Drugs with Direct-Acting Oral Anticoagulants: Risk of Thromboembolic Events
酶诱导抗癫痫药物与直接作用口服抗凝剂的相互作用:血栓栓塞事件的风险
  • 批准号:
    10605482
  • 财政年份:
    2023
  • 资助金额:
    $ 68.12万
  • 项目类别:
The Comparative Effectiveness and Safety of Oral Anticoagulants in Patients with Cirrhosis and Atrial Fibrillation
口服抗凝药对肝硬化合并心房颤动患者的有效性和安全性比较
  • 批准号:
    10559071
  • 财政年份:
    2023
  • 资助金额:
    $ 68.12万
  • 项目类别:
Search for indicators of blood levels of directly inhibitory oral anticoagulants in coagulation tests using artificial intelligence
使用人工智能在凝血测试中搜索直接抑制性口服抗凝剂的血液水平指标
  • 批准号:
    22K07388
  • 财政年份:
    2022
  • 资助金额:
    $ 68.12万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Bleeding on Direct Oral Anticoagulants: Identification of Genetic Risk Factors and a Polygenic Predictive Score in Patients with Atrial Fibrillation
直接口服抗凝剂导致的出血:房颤患者遗传风险因素的鉴定和多基因预测评分
  • 批准号:
    10536789
  • 财政年份:
    2022
  • 资助金额:
    $ 68.12万
  • 项目类别:
Study on proper use of oral anticoagulants combined with 5-fluorouracil
口服抗凝药联合5-氟尿嘧啶正确使用研究
  • 批准号:
    22K06743
  • 财政年份:
    2022
  • 资助金额:
    $ 68.12万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Benchmarking a point-of-care test kit for detection of direct-oral anticoagulants
用于检测直接口服抗凝剂的即时检测试剂盒的基准测试
  • 批准号:
    461790
  • 财政年份:
    2022
  • 资助金额:
    $ 68.12万
  • 项目类别:
    Operating Grants
Direct oral anticoagulants and the risk of colorectal and pancreatic cancers: a population-based cohort study.
直接口服抗凝剂与结直肠癌和胰腺癌的风险:一项基于人群的队列研究。
  • 批准号:
    474475
  • 财政年份:
    2022
  • 资助金额:
    $ 68.12万
  • 项目类别:
    Studentship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了